Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr

  • Posted by: Biocon Biologics

Biocon’s S&P Global ESG Score Improves to 69 for 2024

  • Posted by: Biocon Biologics

U.S. FDA Classifies Biocon Biologics Site in Johor Bahru, Malaysia as Voluntary Action Indicated (VAI)

  • Posted by: Biocon Biologics

Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

  • Posted by: Biocon Biologics

Biocon Biologics Completes One Year as an Integrated Global Biosimilars Enterprise

  • Posted by: Biocon Biologics

Japan Health Authority (PMDA) Approves Biocon Biologics’ Ustekinumab BS, Biosimilar to J&J’s Stelara®

  • Posted by: Biocon Biologics

EMA’s CHMP recommends approval of Biocon Biologics’ YESINTEK®, biosimilar to J&J’s Stelara®

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Honored by ISQ with ‘Jamsetji Tata Award’ for Pioneering Biosciences Movement in India

  • Posted by: Biocon Biologics

Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence

  • Posted by: Biocon Biologics

U.S. FDA Approves Biocon Biologics’ YESINTEK™, Bmab 1200 biosimilar to J&J’s Stelara® (Ustekinumab)

  • Posted by: Biocon Biologics
Share